- Delivering Pan India
Furmecil® (Tegafur, Gimeracil and Oteracil) Tegafur 20 mg + Gimeracil 5.8 mg + Oteracil 15.8 mg capsules by BDR Pharmaceuticals. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Tegafur 20 mg + Gimeracil 5.8 mg + Oteracil 15.8 mg |
|---|---|
| Manufacturer | BDR Pharmaceuticals |
| Country | India |
| Pack size | Tegafur 20 mg + Gimeracil 5.8 mg + Oteracil 15.8 mg: Pack as shown on the carton; please confirm current pack with us |
| Storage | Store in original pack as per carton instructions |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Furmecil® (Tegafur, Gimeracil and Oteracil) Tegafur 20 mg + Gimeracil 5.8 mg + Oteracil 15.8 mg Capsules — Oral Fluoropyrimidine Combination (S-1): A Sourcing Guide for Hospitals and Oncology Pharmacies
Furmecil® is a brand of tegafur, gimeracil and oteracil capsules, an oral fluoropyrimidine combination often referred to as S-1, marketed by BDR Pharmaceuticals. This combination is not marketed under a US FDA label; for reference, the European Medicines Agency describes the equivalent product (Teysuno®) as indicated in adults for advanced gastric cancer when given with cisplatin, and for metastatic colorectal cancer in patients who cannot continue another fluoropyrimidine because of hand-foot syndrome or cardiovascular toxicity. Indications for Furmecil in India are defined by its approved pack insert and the Indian regulator. The decision to prescribe tegafur, gimeracil and oteracil, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Furmecil® (tegafur, gimeracil and oteracil) Tegafur 20 mg + Gimeracil 5.8 mg + Oteracil 15.8 mg capsules to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Furmecil contains three active ingredients in one capsule: tegafur (a prodrug of fluorouracil), gimeracil and oteracil. The carton states tegafur 20 mg, gimeracil 5.8 mg and oteracil 15.8 mg capsules.
How it works, according to the label: According to the EMA, tegafur is converted in the body to fluorouracil (5-FU), a cytotoxic agent. Gimeracil and oteracil are included to modify the exposure to and the gut toxicity of fluorouracil.
The current US prescribing information for the reference product Teysuno® (EMA product information) (DailyMed) lists the following. Indications in India may differ and are defined by the Indian regulator and the Furmecil pack insert.
Details of the evidence behind the combination are published in the EMA assessment for Teysuno. Evidence is cited for information only and is not a recommendation for any patient; the approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Tegafur 20 mg + Gimeracil 5.8 mg + Oteracil 15.8 mg | Capsules (oral) | Pack as shown on the carton; please confirm current pack with us |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology department buyers, and pharmacies that source oral oncology products. This combination is prescribed and supervised by an oncologist.
The EMA reports that, in gastric cancer patients treated with the combination plus cisplatin, the most common severe effects (which may affect more than 1 in 10 patients) are neutropenia, anaemia and fatigue. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Furmecil carton and leaflet, and keep the product in its original pack, out of reach of children.
Furmecil is marketed by BDR Pharmaceuticals. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Furmecil through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Furmecil available in India?
A.K. Pharma supplies Furmecil (tegafur, gimeracil and oteracil) Tegafur 20 mg + Gimeracil 5.8 mg + Oteracil 15.8 mg capsules to hospitals and pharmacies in India. Contact us for current availability.
What does Furmecil contain?
A fixed combination of tegafur, gimeracil and oteracil (S-1) in capsule form, as shown on the carton.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Furmecil be stored?
As printed on the carton and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
